CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cirius Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cirius Therapeutics Inc
12651 High Bluff Drive, Suite 150
Phone: (858) 333-6274p:858 333-6274 SAN DIEGO, CA  92130  United States Fax: (302) 655-5049f:302 655-5049
On 12/20/2019, the Company filed a Registration Withdrawal Request of its Form S-1 (File No. 333-229206) with the SEC, initially filed with the Commission on January 11, 2019.
Business Summary
Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and metabolic diseases. The Company’s lead product candidate, MSDC-0602K, is a novel, once-daily, oral small molecule focused on treating nonalcoholic steatohepatitis, or NASH, with fibrosis. MSDC-0602K selectively modulates the mitochondrial pyruvate carrier, or MPC, which mediates at the cellular level the effects of overnutrition, a cause of NASH and other metabolic disorders.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201812/31/2018YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Business Names
Business Name
CSTX
Octeta Therapeutics

General Information
Number of Employees: 11 (As of 12/31/2018)
Outstanding Shares: 82,307,449 (As of 2/13/2019)
Stock Exchange: NASD
Federal Tax Id: 820928811
Fax Number: (302) 655-5049


Copyright © 2020 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, August 9, 2020